Previously, we reported that breast cancer cells with retinoblastoma (pRb) pathway-defective checkpoints can be specifically targeted with chemotherapeutic agents, following staurosporine-mediated reversible growth inhibition in normal cells. Here we set out to determine if the kinetics of staurosporine-mediated growth inhibition is specifically targeted to the G 1 phase of cells, and if such G 1 arrest requires the activity of wild-type pRb. Normal human mammary epithelial and immortalized cells with intact pRb treated with low concentrations of staurosporine arrested in the G 1 phase of the cell cycle, whereas pRb-defective cells showed no response. The duration of G 1 and transition from G 1 to S phase entry were modulated by staurosporine in Rb-intact cells. In pRb + cells, but not in Rb À cells, low concentrations of staurosporine also resulted in a significant decrease in cyclin-dependent kinase 4 (CDK4) expression and activity. To directly assess the role of pRb in staurosporine-mediated G 1 arrest, we subjected wild-type (Rb +/+ ) and pRb À/À mouse embryo fibroblasts (MEFs) to staurosporine treatments. Our results show that whereas Rb +/+ MEFs were particularly sensitive to G 1 arrest mediated by staurosporine, pRb À/À cells were refractory to such treatment. Additionally, CDK4 expression was also inhibited in response to staurosporine only in Rb +/+ MEFs. These results were recapitulated in breast cancer cells treated with siRNA to pRb to down-regulate the pRb expression. Collectively, our data suggest that treatment of cells with nanomolar concentrations of staurosporine resulted in downregulation of CDK4, which ultimately leads to G 1 arrest in normal human mammary epithelial and immortalized cells with an intact pRb pathway, but not in pRb-null/defective cells.
Introduction
The majority of cancer patients treated today will receive either preoperative or postoperative chemotherapy. However, in many instances, chemotherapeutic regimens are limited by toxic side effects. Healthy proliferating cells, such as the epithelial lining of the intestine, hair follicle cells, and hematopoietic precursors, generally have fast doubling times (1, 2) , making them very sensitive to the effects of chemotherapy.
Myelosuppression, in particular, results in dose reduction and incomplete administration of the prescribed regimens, allowing tumor cells to escape treatment and develop drug resistance (1-3).
Therefore, agents and regimens are required that can exploit differential regulation between normal and tumor cells to protect normal cells from the toxic effects of chemotherapy.
One potential target that is differentially regulated between tumor and normal cells is the retinoblastoma (pRb) pathway, which is central to the G 1 -S transition. Sequential phosphorylation of pRb by various cyclin/cyclin-dependent kinases (CDK) releases pRb from E2F, and enables E2F-dependent gene expression to initiate S and G 2 -M phases of the cell cycle (4) . The pRb protein, or its pathway components (p16, CDK4/6, and cyclin D1), is one of the most frequently altered pathways in many tumors (5) (6) (7) . Such alterations in the pRb pathway lead to a deregulated cell cycle and the ability of the tumors to bypass the G 1 checkpoint (8, 9) .
Our lab previously showed that differences in the G 1 checkpoint between normal and tumor cells can be used to protect normal cells while maintaining efficacy of chemotherapeutic agents against tumor cells. Using an in vitro model, we have described a two-step strategy that optimizes selective targeting of tumor cells (2) . The first step involved using the protein kinase C (PKC) inhibitor staurosporine, which inhibits the proliferation of normal but not tumor cells in a reversible fashion. Subsequently, cells were treated with DNA-damaging agents (i.e., camptothecin or doxorubicin). By pretreating normal cells with staurosporine, the maximum tolerated dose of camptothecin was increased by 2 orders of magnitude. However, in tumor cells treated with staurosporine, the maximum tolerated dose remained unchanged. Of interest, we found that the protection observed was in a p53-independent and pRb-dependent manner. Other labs have similarly shown that the ability of staurosporine to mediate inhibition of cell proliferation is dependent on an intact pRb pathway (3, (10) (11) (12) (13) .
Staurosporine, a microbial alkaloid, was originally discovered as a general PKC inhibitor through screening of the bacterium Streptomyces staurospores. PKC represents a family of phospholipid-dependent serine/threonine kinase with multiple isoforms (a, hI, hII, y, q, g, D, L, A, u, and s) important for proliferation, differentiation, and malignant transformation. Targeting PKC has therefore the potential of modifying malignant growth (14) . Staurosporine is a potent but nonselective inhibitor of PKC capable of inhibiting all the isoforms (15) . Besides PKC, staurosporine has other targets as well, including CDK4/cyclin D1, CDK2/cyclin E, PKA, and mitogen-activated protein kinase (16, 17) . The mechanism underlying the differential effects of staurosporine on the pRb pathway of normal and tumor cells remains unknown. Some have suggested that the effects of staurosporine on the cell cycle are mediated by a number of cell cycle regulators including cyclin E, cyclin D1, CDK2, p18, p21, and p27 (11, 12, (17) (18) (19) (20) (21) (22) . To further examine the mechanism for the differences in staurosporine action between normal and tumor cells, we developed an in vitro model consisting of cell lines with different pRb status. We used normal mortal and immortalized cells with an intact pRb pathway and compared them with immortalized or tumor cells with a defective pRb pathway. The two immortalized, nontumorigenic cell lines 76NE6 (pRb + ) and 76NE7 (pRb À ) are variants of the normal human mammary epithelial cell line 76N, which have been immortalized with the human papillomavirus 16E6 (degrades the p53 protein) or 16E7 (inactivates the pRb protein; refs. [23] [24] [25] [26] [27] [28] [29] [30] . We also directly assessed the role of pRb in staurosporine-mediated G 1 arrest in wild-type (Rb +/+ ) and pRb À/À mouse embryo fibroblasts (MEFs) and Rb siRNAtreated breast cancer cells. Collectively, using the three different cell line models, our data suggest that the pRb pathway is the mediator of G 1 arrest following staurosporine treatment and that cells null/defective in the pRb pathway are refractory to the G 1 -arresting abilities of staurosporine.
Materials and Methods
Cell lines, culture conditions, and materials. The 76NE6 and 76NE7 cell lines, a gift from Dr. V. Band (Northwestern University, Evenston, IL), were immortalized and cultured as previously described (30) (31) (32) . The culture conditions for 76N and 81N normal cell lines, immortalized MCF-10A cell line, and breast cancer MDA-MB-231, HBL100, and MDA-MB436 breast cancer cell lines were previously described (33, 34) . All cells were cultured and treated at 37jC in a humidified incubator containing 6.5% CO 2 . Serum was purchased from HyClone Laboratories (Logan, UT) and cell culture medium was from Life Technologies, Inc. (Rockville, MD). Staurosporine was purchased from Roche Molecular Biochemicals (Indianapolis, IN). The materials for flow cytometry were from Sigma-Aldrich (St. Louis, MO) unless otherwise noted.
siRNA transfections. MDA-MB-231 cells (pRb + ) were transiently transfected with siRNA to pRb (Ambion, Austin, TX) per instructions of the manufacturer. Briefly, cells were harvested with 1Â trypsin (Life Technologies) and inactivated with trypsin inhibitor (Sigma-Aldrich). The cell suspension was brought to a total volume of 1 Â 10 5 /mL in culture medium and kept warm in a 37jC in a humidified incubator. Serum-and growth factor-free medium that contained only 1% 1 mol/L HEPES was used for the transfection (ZAP medium). One hundred microliters of ZAP medium and 8 AL of siPORT Amine (Ambion) transfection reagent were incubated for 10 minutes at room temperature. Simultaneously, 100 AL of ZAP and 30 nmol/L of predesigned siRNA oligos to the Rb1 gene (Ambion) were also incubated for 10 minutes at room temperature. The mixtures containing the transfection reagent and Rb siRNA oligos were then incubated together for an additional 10 minutes. Two hundred microliters of this mixture were then added to each well of an empty six-well plate. Cells (2.3 Â 10 5 ; 2.3 mL) from the cell suspension were then added to each well and allowed to incubate for 24 hours, at which point cells were washed free of transfection reagents and fresh medium was added. Seventy-two hours after transfection, the cells were either treated with 4 nmol/L staurosporine or vehicle (DMSO) control. Cells were incubated for an additional 24 hours, harvested, and subjected to flow cytometric and Western blot analysis.
DNA content analysis. For determination of cell cycle distribution following staurosporine treatment, DNA content was measured by flow cytometry using staurosporine-treated cells that were harvested and stained with propidium iodide alone or in combination with 5-bromo-2-deoxyuridine (BrdUrd). Briefly, 24 hours after plating cells on 150-mm plates, the medium was removed and the cells were treated with staurosporine or fresh medium (control) for 48 hours. The cells were then harvested and 3 Â 10 6 cells were washed with cold PBS. For propidium iodide staining, cell pellets were then fixed overnight with 70% ethanol. Cells were then washed in PBS and stained with a solution of 10 Ag/mL propidium iodide and 20 Ag/mL RNase A in PBTB (PBS with 0.5% Tween 20 and 0.5% bovine serum albumin). Twenty-four hours after staining, 1 Â 10 6 cells were filtered and allowed to incubate at 37j for at least 30 minutes. Cell cycle distribution was acquired with a FACScalibur (Becton Dickinson, San Jose, CA) and the percentage of cells in each phase of the cell cycle was analyzed with ModFit software.
For the pulse-chase BrdUrd labeling experiments, the cells were labeled for 20 minutes with 1 Amol/L BrdUrd at 37jC, followed by either a fresh medium wash or medium plus 4 nmol/L of staurosporine. Time points were set every 3 hours, and after harvesting, the cells were then fixed overnight with 60% ethanol and processed for BrdUrd staining as previously described (35) . For the determination of the fraction of labeled divided cells ( f ld ), the number of divided and undivided labeled (i.e., BrdUrd positive) cells were calculated and divided by the total number of cells stained with propidium iodide.
For the synchronization experiments with nocodazole, cells were treated with either nocodazole alone, staurosporine alone, or nocodazole plus staurosporine. In both cases in which the cells were treated with nocodazole, the cells were treated with 0.125 Ag/mL nocodozole for 12 hours and then washed with either fresh medium (nocodazole alone) or medium plus 4 nmol/L staurosporine (nocodazole plus staurosporine). Cells were harvested every 3 hours and subjected to fluorescence-activated cell sorting analysis.
Western blot analysis and immunoprecipitation kinase assays. Cell lysates were prepared and subjected to Western blot analysis as previously described (36) . Following harvesting, the cells were resuspended in protease phosphatase buffer (25 Ag/mL leupeptin, 25 Ag/mL aprotinin, 10 Ag/mL pepstatin, 1 mmol/L benzamidine, 10 Ag/mL soybean trypsin inhibitor, 0.5 mmol/L phenylmethylsulfonyl fluoride, 50 mmol/L NaF, 0.5 mmol/L sodium orthovanadate) in solution A (27 mmol/L HEPES, 10 mmol/L glucose, 3.3 mmol/L KCl, 13 mmol/L NaCl, 0.5 mmol/L Na 2 HPO 4 , pH 7.6) to prevent protein degradation. Cell lysates were homogenized by sonication followed by centrifugation at 100,000 Â g. The soluble supernatant fraction was removed and protein concentrations were determined with the Bradford assay (Bio-Rad, Hercules, CA). For Western blot analysis, 50 Ag of protein lysate from each condition were electrophoresed in each lane of a 10% (CDK4, CDK2, and actin), 13% (p21, p27 and actin), or 7% (pRb and actin) SDS-PAGE gel and transferred to polyvinylidene difluoride membrane (NEN Life Sciences Products, Inc., Boston, MA) at 4jC, either overnight at constant voltage of 35 mV or for 2.5 hours at a constant voltage of 85 mV. The blots were blocked overnight in BLOTTO (5% nonfat dry milk in 20 mmol/L Tris, 137 mmol/L NaCl, 0.25% Tween, pH 7.6). After washing in TBST (20 mmol/L Tris, 137 mmol/L NaCl, 0.05% Tween, pH 7.6), the blots were incubated in primary antibody for 2.5 hours. Primary antibodies used were pRb (Santa Cruz Biochemicals, Santa Cruz, CA), p21 (Oncogene Research Products/Calbiochem, San Diego, CA), p27, CDK4, and CDK2 (Transduction Laboratories, Lexington, KY), all at 1 Ag/mL, and actin (Chemicon, Temecula, CA) at 0.1 Ag/mL. After incubation with primary antibody, the blots were washed and then incubated in BLOTTO with a secondary antibody and horseradish peroxidase conjugate (Pierce Biotechnology, Inc., Rockford, IL) at a dilution of 1:5,000 for 1 hour. Finally, the blots were again washed and developed in chemiluminescence reagent (NEN/Perkin-Elmer Life Sciences Products, Boston, MA) as directed by the manufacturer. Adding an equal amount of loading dye to the mix stopped the reaction and the samples were then boiled and resolved on a 10% SDS-PAGE gel. The gels were stained, destained, dried, and exposed to X-ray film. For quantitation of relative kinase activity, the bands corresponding to GST-Rb were analyzed on a phosphoimager Typhoon 9400 machine (Amersham Biosciences).
Results
The G 1 phase of the cell cycle is enriched in staurosporinetreated pRb + , but not pRb À , cells. To assess if the pRb status of cells could be a determinant of their sensitivity to staurosporine, [23] [24] [25] [26] [27] [28] [29] [30] . The cells were then harvested and processed for flow cytometric analysis with propidium iodide to stain the cells for DNA content (Fig. 1) . The DNA histogram data of 76NE6 and 76NE7 cells treated with 0 or 4 nmol/L staurosporine reveals that following treatment, 76NE6 cells accumulated in G 1 with a concomitant reduction in S phase, whereas 76NE7 showed no significant perturbation in cell cycle phase distribution (Fig. 1A) . Similarly, all the pRb + cell lines (81N, 76N, and 76NE6) examined responded to staurosporine by accumulation of cells in G 1 phase (Fig. 1B) , whereas all the pRb À cell lines (76NE7, MDA-MB436, and HBL100) showed little to no perturbation in the G 1 phase of the cell cycle in response to range of concentrations of staurosporine and were examined for the expression of key cell cycle proteins. These analysis showed that the levels of CDK4 and pRb and the phosphorylation status of pRb were significantly down-regulated in response to staurosporine in the pRb-positive 76N and 76NE6 cells, but not in 76NE7 cells ( Fig. 2A and B) . Specifically, densitometric analysis showed that treatment of pRb + cells with only 0.5 nmol/L staurosporine results in a 3-and 4-fold decrease in protein levels of CDK4 in the 76N and 76NE6 pRb + cells, respectively (Fig. 2B ). In the pRb À 76NE7 cells, CDK4 levels were minimally modulated by staurosporine. Similar to CDK4, pRb total levels and its CDK4-specific phosphorylation were down-regulated in both 76N and 76NE6 cells. The CDK inhibitor protein p21 is also down-regulated in response to staurosporine in 76N cells. This decrease, however, occurs in a p53-dependent fashion as the levels of p21 are also down-regulated in 76NE7 but not in 76NE6 cells. The levels of p27 and CDK2 were minimally modulated in all the three cell lines.
To examine if the down-regulation of CDK4 by staurosporine in 76NE6 results in the inhibition of CDK4 activity in these cells, we measured CDK4 kinase activity using GST-Rb as a substrate in both 76NE6 and 76NE7 cells treated with staurosporine. The results show that, in response to staurosporine, the CDK4 kinase activity is decreased in 76NE6 cells, whereas the kinase activity remains unabated in 76NE7 cells (Fig. 2C) . These results suggest that the decrease in CDK4 kinase activity could account for staurosporinemediated G 1 arrest in 76NE6 cells.
Lack of G 1 arrest of normal pRb + cells by PKC inhibitor K252A. Because staurosporine was originally discovered as a general PKC inhibitor, we next set out to determine if inhibition of PKC could also result in G 1 arrest of cells. To this end, we treated 76NE6 cells with increasing concentrations of a pure PKC inhibitor (K252A) for 48 hours. Flow cytometric analysis revealed that K252A had very little effect on the cell cycle of 76NE6, resulting in no change in G 1 , S, or G 2 DNA content at low concentrations of the drug. K252A did not increase the G 1 phase at any concentration examined. The only cell cycle perturbation detected was accumulation of cells in G 2 -M phase following treatment of cells with high concentrations of K252A (>65 nmol/L). (Similar G 2 -M accumulation was observed when 76NE6 and 76NE7 cells were treated with concentrations of staurosporine >32 nmol/L; data not shown.) Western blot analysis of K252A-treated cells revealed a different pattern of expression of key cell cycle proteins compared with the staurosporine-treated cells (Fig. 3C) . For example, in response to K252A, the levels of p21, p27, CDK4, and pRb all increased at the highest concentrations, the opposite of what was observed with staurosporine treatment (Fig. 2) . Because K252A did not mediate G 1 arrest or modulate the levels of key cell cycle proteins at concentrations that inhibit PKC, the G 1 arrest mediated by staurosporine is most likely independent of PKC inhibition.
Staurosporine inhibits S-phase synthesis and progression in pRb + cells, but not in pRb À cells. The results from the DNA histogram analysis (Fig. 1) suggested that staurosporine mediates G 1 arrest concomitant with a decrease of cells in S phase. However, such analysis is not sufficient to examine the rate and progression of DNA synthesis in response to staurosporine treatment. To directly address this question, we used a three-pronged approach to measure the rate of DNA synthesis and progression of S-phase BrdUrd incorporation into DNA. Initially, we examined the temporal effect of staurosporine on the cascade of events leading to G 1 arrest of cells. For this purpose, the staurosporine-responsive pRb + 76NE6 cells were treated with 4 nmol/L staurosporine and harvested for flow cytometry and BrdUrd analysis at 3-hour intervals for 24 hours to examine DNA content and modulation of rate of DNA synthesis (Fig. 4) . Flow cytometry reveals that G 1 arrest initiates as early as 3 hours after treatment (Fig. 4A) . This is further confirmed by a decrease in the BrdUrd staining, indicating a decrease in the rate of DNA synthesis (Fig. 4B) . To determine whether the effect of staurosporine was reversible, following 24 hours of continuous exposures of cells to 4 nmol/L staurosporine, (Fig. 4B) and flow cytometry analysis (data not shown) showed that removal of drug results in the resumption of DNA synthesis.
Next, to examine the role of staurosporine in modulating the progression of cells from G 1 to S phase, we used a ''pulse-chase'' strategy of BrdUrd incorporation (Fig. 5A and B) . As schematically depicted in Fig. 5A, 76NE6 and 76NE7 cells were treated with BrdUrd for 20 minutes and then fresh medium in the presence or absence of 4 nmol/L staurosporine was added to the cells. At 3-hour intervals following BrdUrd treatment F4 nmol/L staurosporine, cells were harvested and subjected to a two-color flow cytometric analysis with propidium iodine and BrdUrd. The results are presented as fraction of labeled divided cells ( f ld ), representing the number of divided (or undivided) BrdUrd labeled cells as a fraction of the total number of cells stained with propidium iodide (Fig. 5B) .
Figure 5B (Fig. 5B, left, closed  symbol) . Specifically, when cells reach the G 1 phase of the cell cycle (12 hours post BrdUrd labeling), there is no decrease in the amount of divided cells, indicating that cells have remained in the G 1 phase for the duration of the experiment. In the 76NE7 pRb À cells (Fig. 5B, right) , on the other hand, there is no perturbation of progression of cells through the different phases of the cell cycle in the presence or absence of staurosporine as measured by the fraction of BrdUrd-labeled and divided cells. The third approach we took to examine the role of staurosporine in perturbing the progression of cells through different phases of the cell cycle was to first arrest the cells in G 2 -M phase by a reversible mitotic blocker (i.e., nocodazole), release the cells from arrest, and then treat the cells with staurosporine ( Fig. 5C and D) . The question being addressed here is if pRb + cells, following arrest in G 2 -M, can be subsequently arrested in the G 1 phase of the cell cycle by staurosporine. To address this question, we treated 76NE6 and 76NE7 cells with staurosporine alone (4 nmol/L), nocodazole alone, and nocodazole plus staurosporine. The scheme of the sequence of treatment with each condition is depicted in Fig. 5C . Following the different treatments, cells were subjected to flow cytometric analysis (Fig. 5D) . The results revealed that whereas both cell lines were synchronized reversibly in the G 2 -M phase of the cell cycle (open circles), only the 76NE6 cells were further arrested in the G 1 phase by staurosporine (shaded diamonds) and the 76NE7 cells continued through the cycle and were unperturbed by staurosporine. Specifically, in 76NE7 cells, the nocodazole alone and nocodazole plus staurosporine treatment arms resulted in identical progression out of G 1 phase (suggesting no arrest induced by staurosporine), whereas in 76NE6 cells, the nocodazole plus staurosporine-treated cells remained in the G 1 phase of the cell cycle and the nocodazole alone-treated cells progressed through G 1 . Collectively, the results from Figs. 4 and 5 suggest that staurosporine can perturb the cell cycle of pRb + cells, but not of pRb À cells.
pRb is directly modulated by staurosporine in mediating G 1 arrest. We next set out to directly examine the role of pRb in staurosporine-mediated G 1 arrest in the nonmalignant 76NE6 cells. To this end, mouse embryo fibroblasts from wild-type and pRb À/À mice (37, 38) were cultured and subjected to treatment with increasing concentrations of staurosporine ( Fig. 6A and B) . Flow cytometric analysis of treated cells indicated that whereas pRb +/+ MEFs were very sensitive to staurosporine and accumulated in the G 1 phase of the cell cycle starting at 2 nmol/L (Fig. 6A, top) , the pRb À/À MEFs were refractory to the cell cycle modulatory effects of staurosporine (Fig. 6A, bottom) . The relative fold change of cells in G 1 phase in response to staurosporine treatment was 2.5-fold higher for pRb +/+ MEFs as compared with pRb À/À MEFs (Fig. 6B,  left) . Western blot analysis revealed that CDK4 levels plummeted in response to staurosporine in pRb +/+ cells, at concentrations as low as 1 nmol/L, whereas in pRb À/À MEFs, CDK4 basal levels were minimally decreased by staurosporine. CDK2 levels remained unaltered in both cells following staurosporine treatment (Fig. 6B,  right) . The role of pRb was also assessed by down-regulation of pRb using siRNA in MDA-MB-231 cells that are wild-type for pRb ( Fig. 6C and D) . Down-regulation of pRb by siRNA resulted in a significant reduction in the amount of cells that accumulated in the G 1 phase of the cell cycle (Fig. 6C) . In these cells, the pRb protein was completely down-regulated by Rb siRNA sequences (Fig. 6D) . The results from Fig. 6 suggest that staurosporine mediates G 1 arrest directly through the pRb pathway.
Discussion
Previous studies in our laboratory had investigated the use of staurosporine, a cytostatic drug, for protection of normal cells from the toxic effects of chemotherapy. From these studies, we determined that staurosporine, at low concentrations, maintains normal cells, but not tumor cells, in a reversible G 0 -G 1 state. After treating the cells with staurosporine, the cells were subsequently treated with DNA-damaging agents (doxorubicin or camptothecin). The normal cells were protected due to the staurosporinemediated G 1 arrest, without compromise of chemotoxicity against the tumor cells. The protection observed was in a p53-independent and pRb-dependent manner (2) . Other labs have similarly revealed the importance of pRb in the staurosporine-mediated G 1 arrest process (3, (10) (11) (12) (13) .
In this article, we present a model for the staurosporine-mediated protection of nonmalignant cells with an intact Rb pathway. We find The paired t test was done with a 95% confidence interval: *, P = 0.05; **, P = 0.001. D, cell lysates from the same samples were prepared and subjected to Western blot analysis with the indicated antibodies, with actin for equal loading.
that staurosporine acts directly on the pRb pathway and results in the decrease of CDK4 expression. The resultant decrease in CDK4 protein levels leads to inactivation of CDK4, which is no longer able to phosphorylate pRb. With CDK4 no longer active, pRb remains hypophosphorylated, leading to the G 1 arrest.
The scenario described above is applicable to our immortalized cell model of 76NE6 (pRb + /p53 À ) cells, in which case p21 regulation is p53 independent. However, in the case of our normal mortal cells, which are p53 + , p21 is p53 dependent and follows the same expression pattern as p53. In the normal cells (p53 + /pRb + ), CDK4 plays a greater role in the staurosporine-mediated G 1 arrest because in these cells, we do not see an increase in p21, only an increase in p27 at the higher concentrations of staurosporine. Furthermore, the pRb + 76NE6 cells have a lower concentration of CDK4 protein than the pRb À 76NE7 cells. In the pRb + 76NE6 cells, any slight change in CDK4 expression level has a marked effect on the cell cycle, in this case leading to a G 1 arrest. Staurosporine may have no effect on cells with overexpression of CDK4 regardless of pRb status. Staurosporine may be able to reduce the amount of CDK4 in these cells, but such reduction is not sufficient to mediate a G 1 arrest. Additionally, the remaining amount of CDK4 in these pRb À cells may be enough to keep p21 bound and allow CDK4 to remain active. Therefore, in tumors that still have an intact pRb protein, but overexpressing CDK4, staurosporine will not protect these cells but will still protect the normal cells.
The idea for a protection strategy was described in the 1970s by several labs (39) (40) (41) . However, since then, most labs have focused on the ability to increase the toxicity to tumor cells with existing agents by abrogating the S or G 2 -M phase of the cell cycle. An example of this is the staurosporine analogue 7-hydroxystaurosporine (UCN-01). When used after the addition of cytotoxic agents (i.e., camptothecin or fludarabine nucleoside), UCN-01 has proved to enhance the cytotoxicity of these agents (42) (43) (44) (45) (46) .
Our strategy is different, however, because we are treating the cells with staurosporine beforehand to protect the normal cells from the cytotoxic agent, instead of enhancing the effect of the cytotoxic agent on the tumor cells. Both strategies are taking advantage of the cell cycle and are important for understanding the drugs we use for chemotherapy.
In an in vitro setting, staurosporine has proved to be a very promising agent in the strategy to protect normal cells from the toxic effects of chemotherapeutic agents. However, in trials with UCN-01, it has been shown to bind to the a1 acid glycoprotein in human plasma, causing a prolonged half-life of the drug and low clearance (47, 48) . This could be a limitation with staurosporine in vivo and has been shown to be a hindrance in several studies with UCN-01 (49) (50) (51) (52) . The clinical limitations noted with UCN-01 highlight the need for additional understanding of drug metabolism, half-life, and reversibility before implementation of a protection strategy in cancer patients.
